FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362591410> ?p ?o ?g. }

• W4362591410 endingPage "S104" @default.
• W4362591410 startingPage "S103" @default.
• W4362591410 abstract "TGD modeling using sum of longest diameters (SLD) is associated with long-term outcomes in NSCLC. Early changes in radiomics features within the tumor may also correlate with survival outcomes. We retrospectively evaluated 3 methods to assess early treatment outcomes: tumor growth rate (g) by SLD, volumetric measurements, and change in radiomics signatures to predict survival outcomes in NSCLC. Patients with stage IV NSCLC in CheckMate 9LA treated with first-line nivolumab+ipilimumab+chemotherapy (NIVO+IPI+CHEMO) or CHEMO alone were included. TGD was modeled using radiologically-assessed SLD from ≤5 target lesions or sum of volumes (SVOL) from all measurable lesions >10 mm at baseline, 6, 12, and/or 18 weeks. Measurements were fitted to the TGD model. 1Fojo AT et al. J Clin Oncol. 2022;40(16_suppl):Abst 9063. Overall survival (OS) for each growth quartile was estimated by Kaplan–Meier curves. Changes in radiomic features from all measurable lesions >10 mm were assessed at week 6 and 12. At week 18, low SVOL- and SLD-derived g values were associated with longer median OS across both treatment arms. SVOL-derived g values were more consistent across timepoints if evaluated at week 12 and 18 than SLD-derived g values. Delta radiomics signatures to predict long-term OS at week 6 (table) and 12 performed better than RECIST 1.1 in the NIVO+IPI+CHEMO arm. Table 111PMedian OS in groups defined by unidimensional vs volumetric estimates of tumor growth, and by RECIST 1.1 criteria of response vs delta radiomics signatureMedian OS, monthsSLD measurementsaFour timepoints, week 18. Patients were grouped according to quartiles of g, with quartile 1 representing the subgroup with slowest g.SVOL measurementsaFour timepoints, week 18. Patients were grouped according to quartiles of g, with quartile 1 representing the subgroup with slowest g.NIVO +IPI +CHEMOCHEMO aloneNIVO +IPI +CHEMOCHEMO aloneg quartile1 g25.817.926.419.1quartile412.59.511.68.2Median OS, monthsRECIST response (NIVO IPI+CHEMO)Delta radiomics-derived response (NIVO+IPI +CHEMO)At 6 weeksAt 6 weeksProgressive disease7.17.4Stable disease15.014.5Partial or complete response32.54a Four timepoints, week 18. Patients were grouped according to quartiles of g, with quartile 1 representing the subgroup with slowest g. Open table in a new tab SVOL-derived g values correlate with longer OS and are more consistent across timepoints than SLD-derived g values at 18 weeks of treatment. Delta radiomics signatures as early as 6 weeks on-treatment were better than RECIST in identifying patients with NSCLC deriving long-term OS benefit. Both findings can potentially inform early decision making in clinical trials and real-world use." @default.
• W4362591410 created "2023-04-06" @default.
• W4362591410 creator A5001221830 @default.
• W4362591410 creator A5013662643 @default.
• W4362591410 creator A5019312385 @default.
• W4362591410 creator A5023329393 @default.
• W4362591410 creator A5027391873 @default.
• W4362591410 creator A5038114191 @default.
• W4362591410 creator A5044898761 @default.
• W4362591410 creator A5046819741 @default.
• W4362591410 creator A5050503037 @default.
• W4362591410 creator A5052048067 @default.
• W4362591410 creator A5075354592 @default.
• W4362591410 date "2023-04-01" @default.
• W4362591410 modified "2023-09-25" @default.
• W4362591410 title "111P Application of radiomics signatures and unidimensional vs volumetric measurement of early tumor growth dynamics (TGD) to predict first-line treatment outcomes in patients with stage IV non-small cell lung cancer (NSCLC)" @default.
• W4362591410 doi "https://doi.org/10.1016/s1556-0864(23)00366-0" @default.
• W4362591410 hasPublicationYear "2023" @default.
• W4362591410 type Work @default.
• W4362591410 citedByCount "0" @default.
• W4362591410 crossrefType "journal-article" @default.
• W4362591410 hasAuthorship W4362591410A5001221830 @default.
• W4362591410 hasAuthorship W4362591410A5013662643 @default.
• W4362591410 hasAuthorship W4362591410A5019312385 @default.
• W4362591410 hasAuthorship W4362591410A5023329393 @default.
• W4362591410 hasAuthorship W4362591410A5027391873 @default.
• W4362591410 hasAuthorship W4362591410A5038114191 @default.
• W4362591410 hasAuthorship W4362591410A5044898761 @default.
• W4362591410 hasAuthorship W4362591410A5046819741 @default.
• W4362591410 hasAuthorship W4362591410A5050503037 @default.
• W4362591410 hasAuthorship W4362591410A5052048067 @default.
• W4362591410 hasAuthorship W4362591410A5075354592 @default.
• W4362591410 hasBestOaLocation W43625914101 @default.
• W4362591410 hasConcept C10515644 @default.
• W4362591410 hasConcept C121608353 @default.
• W4362591410 hasConcept C126322002 @default.
• W4362591410 hasConcept C126838900 @default.
• W4362591410 hasConcept C143998085 @default.
• W4362591410 hasConcept C146357865 @default.
• W4362591410 hasConcept C151730666 @default.
• W4362591410 hasConcept C2776256026 @default.
• W4362591410 hasConcept C2776694085 @default.
• W4362591410 hasConcept C2777701055 @default.
• W4362591410 hasConcept C2778559731 @default.
• W4362591410 hasConcept C2778822529 @default.
• W4362591410 hasConcept C2779984678 @default.
• W4362591410 hasConcept C2780030458 @default.
• W4362591410 hasConcept C2989005 @default.
• W4362591410 hasConcept C44249647 @default.
• W4362591410 hasConcept C68443243 @default.
• W4362591410 hasConcept C71924100 @default.
• W4362591410 hasConcept C86803240 @default.
• W4362591410 hasConceptScore W4362591410C10515644 @default.
• W4362591410 hasConceptScore W4362591410C121608353 @default.
• W4362591410 hasConceptScore W4362591410C126322002 @default.
• W4362591410 hasConceptScore W4362591410C126838900 @default.
• W4362591410 hasConceptScore W4362591410C143998085 @default.
• W4362591410 hasConceptScore W4362591410C146357865 @default.
• W4362591410 hasConceptScore W4362591410C151730666 @default.
• W4362591410 hasConceptScore W4362591410C2776256026 @default.
• W4362591410 hasConceptScore W4362591410C2776694085 @default.
• W4362591410 hasConceptScore W4362591410C2777701055 @default.
• W4362591410 hasConceptScore W4362591410C2778559731 @default.
• W4362591410 hasConceptScore W4362591410C2778822529 @default.
• W4362591410 hasConceptScore W4362591410C2779984678 @default.
• W4362591410 hasConceptScore W4362591410C2780030458 @default.
• W4362591410 hasConceptScore W4362591410C2989005 @default.
• W4362591410 hasConceptScore W4362591410C44249647 @default.
• W4362591410 hasConceptScore W4362591410C68443243 @default.
• W4362591410 hasConceptScore W4362591410C71924100 @default.
• W4362591410 hasConceptScore W4362591410C86803240 @default.
• W4362591410 hasIssue "4" @default.
• W4362591410 hasLocation W43625914101 @default.
• W4362591410 hasOpenAccess W4362591410 @default.
• W4362591410 hasPrimaryLocation W43625914101 @default.
• W4362591410 hasRelatedWork W167319750 @default.
• W4362591410 hasRelatedWork W2055244776 @default.
• W4362591410 hasRelatedWork W2413020017 @default.
• W4362591410 hasRelatedWork W2544577077 @default.
• W4362591410 hasRelatedWork W2743577629 @default.
• W4362591410 hasRelatedWork W2767479818 @default.
• W4362591410 hasRelatedWork W2904759734 @default.
• W4362591410 hasRelatedWork W2955084311 @default.
• W4362591410 hasRelatedWork W3097428643 @default.
• W4362591410 hasRelatedWork W4307756429 @default.
• W4362591410 hasVolume "18" @default.
• W4362591410 isParatext "false" @default.
• W4362591410 isRetracted "false" @default.
• W4362591410 workType "article" @default.